Session

PP 05 IBD (Posters)

WHAT IS THE REAL IMPACT OF THE HLA-DQA1*05 POLYMORPHISM ON INFLIXIMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE?
WHAT IS THE REAL IMPACT OF THE HLA-DQA1*05 POLYMORPHISM ON INFLIXIMAB TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE?

IN A PRECLINICAL MOUSE MODEL OF ULCERATIVE COLITIS, PANCREASTATIN INHIBITION REGULATES COLONIC MUCOSAL BARRIER FUNCTION IN A SEX-DEPENDENT MANNER
IN A PRECLINICAL MOUSE MODEL OF ULCERATIVE COLITIS, PANCREASTATIN INHIBITION REGULATES COLONIC MUCOSAL BARRIER FUNCTION IN A SEX-DEPENDENT MANNER

PROACTIVE THERAPEUTIC DRUG MONITORING FOR INFLIXIMAB MAY REDUCE STEROID EXPOSURE IN IBD
PROACTIVE THERAPEUTIC DRUG MONITORING FOR INFLIXIMAB MAY REDUCE STEROID EXPOSURE IN IBD

RISK FOR BACTERIAL INFECTIONS AMONG INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH BIOLOGICAL AGENTS
RISK FOR BACTERIAL INFECTIONS AMONG INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH BIOLOGICAL AGENTS

VOLUMETRIC MEASUREMENT OF CROHN’S DISEASE ON MAGNETIC RESONANCE ENTEROGRAPHY: FEASIBILITY, CLINICAL UTILITY, AND ROLE IN ASSESSING TREATMENT RESPONSE
VOLUMETRIC MEASUREMENT OF CROHN’S DISEASE ON MAGNETIC RESONANCE ENTEROGRAPHY: FEASIBILITY, CLINICAL UTILITY, AND ROLE IN ASSESSING TREATMENT RESPONSE

COMPARATIVE MULTI-OMICS ANALYSIS IN PERIPHERAL BLOOD IDENTIFIES UNIQUE AND SHARED CORE MOLECULAR SIGNATURES IN IBD, PSORIASIS, RHEUMATOID ARTHRITIS AND SLE
COMPARATIVE MULTI-OMICS ANALYSIS IN PERIPHERAL BLOOD IDENTIFIES UNIQUE AND SHARED CORE MOLECULAR SIGNATURES IN IBD, PSORIASIS, RHEUMATOID ARTHRITIS AND SLE

PROTON PUMP INHIBITORS ARE ASSOCIATED WITH A DISABLING COURSE OF CROHN’S DISEASE
PROTON PUMP INHIBITORS ARE ASSOCIATED WITH A DISABLING COURSE OF CROHN’S DISEASE

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE

SIMPLE SCORING QUESTIONNAIRE FOR ASSESSMENT OF DISEASE SEVERITY AND QUALITY OF LIFE
SIMPLE SCORING QUESTIONNAIRE FOR ASSESSMENT OF DISEASE SEVERITY AND QUALITY OF LIFE

THROMBOEMBOLIC EVENTS IN CROHN'S DISEASE: AN EXTRA-DIGESTIVE COMPLICATION TO BE FEARED
THROMBOEMBOLIC EVENTS IN CROHN'S DISEASE: AN EXTRA-DIGESTIVE COMPLICATION TO BE FEARED

EPIDEMIOLOGICAL PROFILE AND MANAGEMENT OF SPECIFIC ANAL FISTULAS
EPIDEMIOLOGICAL PROFILE AND MANAGEMENT OF SPECIFIC ANAL FISTULAS

A SPECIFIC MICROBIOTA SIGNATURE IS ASSOCIATED TO IMMUNOTHERAPY-RELATED COLITIS AS ASSESSED BY A MACHINE LEARNING APPROACH – A COMPARATIVE STUDY WITH INFLAMMATORY BOWEL DISEASES AND HEALTHY CONTROLS
A SPECIFIC MICROBIOTA SIGNATURE IS ASSOCIATED TO IMMUNOTHERAPY-RELATED COLITIS AS ASSESSED BY A MACHINE LEARNING APPROACH – A COMPARATIVE STUDY WITH INFLAMMATORY BOWEL DISEASES AND HEALTHY CONTROLS

CIRCULATING CELL-FREE DNA AND MITOCHONDRIAL DNA PREDICT DISEASE ACTIVITY IN PAEDIATRIC-ONSET INFLAMMATORY BOWEL DISEASE
CIRCULATING CELL-FREE DNA AND MITOCHONDRIAL DNA PREDICT DISEASE ACTIVITY IN PAEDIATRIC-ONSET INFLAMMATORY BOWEL DISEASE

INTERROGATION OF DIET-INDUCED CHANGES IN THE MICROBIOME USING METAPROTEOMIC ANALYSIS OF CROHN’S DISEASE PATIENTS RECEIVING A CATERED HIGH FIBER, LOW FAT DIET INTERVENTION
INTERROGATION OF DIET-INDUCED CHANGES IN THE MICROBIOME USING METAPROTEOMIC ANALYSIS OF CROHN’S DISEASE PATIENTS RECEIVING A CATERED HIGH FIBER, LOW FAT DIET INTERVENTION

IMPLEMENTATION OF CANCER PREVENTION TO PATIENTS WITH INFLAMMATORY BOWEL DISEASE ACCORDING TO RECOMMENDATION - HOW IT WORKS IN EVERYDAY PRACTICE ? RESULTS OF ONE CENTER CROSS-SECTIONAL STUDY
IMPLEMENTATION OF CANCER PREVENTION TO PATIENTS WITH INFLAMMATORY BOWEL DISEASE ACCORDING TO RECOMMENDATION - HOW IT WORKS IN EVERYDAY PRACTICE ? RESULTS OF ONE CENTER CROSS-SECTIONAL STUDY

PRA023 IMPROVED HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY IBDQ-32 IN A PHASE 2 TRIAL FROM PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
PRA023 IMPROVED HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY IBDQ-32 IN A PHASE 2 TRIAL FROM PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

NONINVASIVE TRANSCUTANEOUS AURICULAR VAGUS NERVE STIMULATION MODULATES PRO-APOPTOTIC AND PRO-SURVIVAL MOLECULES AND ANTI-INFLAMMATORY CYTOKINES IN A PRECLINICAL MODEL OF ULCERATIVE COLITIS
NONINVASIVE TRANSCUTANEOUS AURICULAR VAGUS NERVE STIMULATION MODULATES PRO-APOPTOTIC AND PRO-SURVIVAL MOLECULES AND ANTI-INFLAMMATORY CYTOKINES IN A PRECLINICAL MODEL OF ULCERATIVE COLITIS

THE POCER INDEX: APPLICATION OF A NOVEL ENDOSCOPIC SCORE IN A REAL-LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE AFTER SURGERY
THE POCER INDEX: APPLICATION OF A NOVEL ENDOSCOPIC SCORE IN A REAL-LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE AFTER SURGERY

MUCOSA-ASSOCIATED COLLAGENOUS COLITIS MICROBIOTA IN-DEPTH ANALYSIS IDENTIFIES POTENTIAL DISEASE TRIGGERS
MUCOSA-ASSOCIATED COLLAGENOUS COLITIS MICROBIOTA IN-DEPTH ANALYSIS IDENTIFIES POTENTIAL DISEASE TRIGGERS

LONG-TERM RISK OF DELAYED POSTOPERATIVE CROHN’S DISEASE RECURRENCE IN PATIENTS WITH NO OR MILD RECURRENCE AT FIRST ENDOSCOPIC ASSESSMENT
LONG-TERM RISK OF DELAYED POSTOPERATIVE CROHN’S DISEASE RECURRENCE IN PATIENTS WITH NO OR MILD RECURRENCE AT FIRST ENDOSCOPIC ASSESSMENT

Item 441 - 460 / 826
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42